<DOC>
	<DOC>NCT01026285</DOC>
	<brief_summary>International Observational Registry on Schizophrenia</brief_summary>
	<brief_title>InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics</brief_title>
	<detailed_description>This is an observational, non-interventional registry designed to assess medication usage patterns and to explore, in clinical routine practice, long-term outcomes and relevant factors for patient adherence to treatment, in patients receiving antipsychotic treatment with risperidone long-acting injectable (RLAI) or oral antipsychotics. Six month retrospective data and 1 year prospective data will be collected. According to label</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients must satisfy the following criteria to be eligible for documentation in this noninterventional study: Diagnosis of schizophrenia as well as 6 months of retrospective clinical records Newly initiated on or switched to RLAI or an oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago Signed informed consent (either signed by the patient or his/her legal representative) is available at the beginning of documentation any schizophrenic patient (including those for whom a legal representative must sign consent) can be involved in the study Established treatment refractory schizophrenia, defined as treatment failures with adequate trials (adequate as judged by the treating physician) of more than 2 second generation (atypical) antipsychotics and/or clozapine History of neuroleptic malignant syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Risperdal Consta</keyword>
</DOC>